# Viva Biotech Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viva-biotech-holdings

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.vivabiotech.com.cn
- Total disclosed funding: $3M
- Latest round: Series A (Sep 9, 2009)
- Investors on record: 1

## About

Based in Shanghai, China, and established in 2008, Viva Biotech (Shanghai) Ltd. is a biotechnology company that provides Contract Research Organizations (CRO) drug discovery services and Contract Manufacturing and Development Organization (CMDO) services throughout the whole drug production process. The company has passed ISO14001, ISO45001, and the EHS management system. In May 2019, it was listed on Hong Kong Stock Exchange under the number 01873. HK. As of December 31, 2021, it has provided drug R&D and production services to 1,820 biotech and pharmaceutical clients around the world. Besides, it invested in and incubated 87 start-up biotech companies in total. In June 2023, HighLight Capital, Temasek Holdings, and Truelight Capital agreed to invest USD 150 million in Viva Biotech (Shanghai) Ltd.

The company provides one-stop services from early-stage structure-based drug R&D to commercial drug delivery. The company's product lines include cell lines, crystal structures, G Protein-Coupled Receptors (GPCR) proteins, antibodies, and other proteins. Its business is divided into three series, which include CRO drug development services, CDMO R&D and manufacturing services, EFS investment, and incubation business.

The revenue and net income of the company in 2022 were CNY 2.379 billion and CNY -504.22 million, respectively.

## Funding rounds

- Series A, Sep 9, 2009, $3M — Avenue Capital Group

## Investors

- Avenue Capital Group (https://capitalatlas.ai/funds/avenue-capital-group) — Series A